ProfileGDS5678 / 1424329_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 68% 68% 61% 67% 70% 52% 67% 68% 67% 73% 69% 69% 68% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.1473568
GSM967853U87-EV human glioblastoma xenograft - Control 24.1582668
GSM967854U87-EV human glioblastoma xenograft - Control 33.6367361
GSM967855U87-EV human glioblastoma xenograft - Control 44.10767
GSM967856U87-EV human glioblastoma xenograft - Control 54.3305270
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3449552
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.1426567
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1281368
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0918367
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.7406873
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2781369
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2754569
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1487768
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1424668